Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 4

2(28.6%)

N/A

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(3)

Phase 4(2)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04895293Phase 1Completed

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

Role: lead

NCT02315170Not ApplicableCompleted

Assessment of Novel Intraocular Injection Guide

Role: lead

NCT02732899Phase 2Completed

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

Role: lead

NCT02357342Phase 2Completed

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Role: lead

NCT01309451Phase 4Completed

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

Role: lead

NCT02127684Phase 2Withdrawn

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

Role: lead

NCT01085734Phase 4Completed

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

Role: lead

All 7 trials loaded